Journal of Exploratory Research in Pharmacology

Journal Information
EISSN : 2572-5505
Current Publisher: Xia & He Publishing (10.14218)
Total articles ≅ 67
Filter:

Latest articles in this journal

Anamika Banerjee, Sunil Kumar Malonia, Shubham Dutta
Journal of Exploratory Research in Pharmacology; doi:10.14218/jerp.2020.00033

Gong Feng, Lanjing Zhang, Ke Wang, Bohao Chen, Harry Hua-Xiang Xia
Journal of Exploratory Research in Pharmacology; doi:10.14218/jerp.2021.00004

Hakim Rahmoune, Nada Boutrid
Journal of Exploratory Research in Pharmacology; doi:10.14218/jerp.2020.00025

Kim Lawson, Attam Singh, Ilya Kantsedikas, Christopher Arthur Jenner, Daniel Keith Austen
Journal of Exploratory Research in Pharmacology; doi:10.14218/jerp.2020.00043

Sy Giin Chong, Ciaran Scallan, Patrick Gerard Cox
Journal of Exploratory Research in Pharmacology; doi:10.14218/jerp.2020.00040

Roha Tariq, Usama Ahmed Khalid, Samra Kanwal, Fazal Adnan, Muhammad Qasim
Journal of Exploratory Research in Pharmacology; doi:10.14218/jerp.2020.00036

Fu-Bin Zhu, Qi-Heng Gou, Lin-Yong Zhao
Journal of Exploratory Research in Pharmacology; doi:10.14218/jerp.2020.00035

Abstract:
The rearrangement during transfection (RET) encodes a receptor tyrosine kinase (RTK), which is involved in the development of various tissues and cells. The rearrangements and mutations of RET contribute to the development of a variety of human malignancies. Therefore, RET alterations are novel therapeutic targets. Inhibitors for RET and other kinases have been approved for the treatment of RET-altered tumors and have demonstrated their benefits for some types of cancer patients in clinics. However, due to off-target effects, these inhibitors have some adverse effects and dose-limiting toxicity. Therefore, long-term treatment with these inhibitors has potential limitations. Novel highly selective inhibitors (pralsetinib and selpercatinib) that target the RET pathway are well tolerated and have significant and long-lasting antitumor activity. They have been accelerated for approval by the FDA. This article will focus on the role of highly selective inhibitors targeting the RET and their efficacy and safety in therapy for RET-associated cancers.
Karol Wróblewski
Journal of Exploratory Research in Pharmacology; doi:10.14218/jerp.2020.00041

Back to Top Top